Introduction
Despite important advances in the management of the acute leukaemias there has been little significant progress in the treatment of chronic granulocytic leukaemia (C.G.L.) (Galton and Spiers, 1971) . Fifty years ago the median survival from diagnosis of untreated patients with C.G.L. was 19 months (Minot et al., 1924) . In a Medical Research Council study in 1968 the median survival of patients who received splenic irradiation was 28 months while patients treated with busulphan fared better at 39 5 months (Medical Research Council, 1968) . A retrospective comparison of radiotherapy and busulphan (Monfardini et al., 1973) and a study of C.G.L. treated with dibromannitol (Dibromannitol Study Group, 1973) showed similar results. Though current therapy for C.G.L. improves the quality of life it seems to add only about 20 months to its duration. Despite its small effect upon survival busulphan therapy remains popular because of its convenience and good short-term results; this has retarded research into other forms of treatment for C.G.L. (Galton and Spiers, 1971) .
In the Medical Research Council's study over 70% of the patients died with uncontrolled leukaemia. Their disease had undergone metamorphosis (Baikie, 1966 (Baikie, , 1969 to a more refractory neoplasm in which the features of C.G.L. in its chronic phase were partly or wholly lost. Despite some recent improvement (Spiers et al., 1974) treatment is still not strikingly effective once metamorphosis has occurred and measures aimed at postponing the onset of this change and prolonging the chronic phase of C.G.L. may be the most promising way of improving survival in this disease. We have previously suggested (Baikie, 1968; Galton and Spiers, 1971; Spiers, 1973 ) that elective splenectomy early in the course of C.G.L. might prolong survival by deferring metamorphosis. Patients with C.G.L. who have enjoyed especially long survival seem to include an undue proportion with relatively slight splenomegaly before treatment or prolonged regression of splenic enlargement after treatment. A few patients with C.G.L. who underwent splenectomy for a variety of reasons have had haematological remissions without chemotherapy (Cutting, 1967) or unusually long survivals (Dubois-Ferriere and Rudler, 1967; Meeker et al., 1967) . The spleen in C.G.L. is known to contain Philadelphia (Phl)-positive cells before metamorphosis has occurred and Phlpositive cells with additional chromosomal changes after metamorphosis (Spiers and Baikie, 1965; 1968) . The proliferative activity of immature granulocytic cells in the spleen differs from that observed in the bone marrow (Brandt, 1969; Galbraith, 1969) , and recent cytogenetic observations suggest that the spleen may sometimes have a primary role in the development of aneuploid clones of leukaemia cells which lead to metamorphosis of C.G.L. (Hossfeld and Schmidt, 1973; Mitelman, et al., 1974) . Pharmacodynamic or, possibly, immunological factors may make the spleen a particularly suitable site for the emergence of aberrant clones, and if so its removal could be expected to postpone metamorphosis though it might not prevent it. The beneficial effects of prior splenectomy certainly extend beyond the time when metamorphosis has actually occurred. Refractory splenomegaly with pain, anaemia, a high transfusion requirement, and thrombocytopenia which is not corrected by platelet transfusion are commonly encountered in the terminal phase of C.G.L. The absence of these complications improves the quality of life and probably also its duration even though the C.G.L.
is no longer chronic (Schwarzenberg et al., 1973; Spiers et al., 1973) . Some of these considerations were felt to justify a pilot study of elective splenectomy in C.G.L., and we now report the results nine years from its inception. The patients were nursed preoperatively in general medical wards and after operation in general surgical wards. They were not neutropenic and no special isolation measures were adopted. Most of the splenectomies were performed via an upper left paramedian incision confined to the abdomen. Some of the more recent operations were performed with intermittent calf compression before and after the operation (Hills et al., 1972) and the use of 125I-fibrinogen for the detection of postoperative venous thrombosis (Jeyasingh et al., 1972) . Postoperative anticoagulants were not routinely used.
Patients and Methods
The follow-up and, in 24 cases, the medical care of these patients after splenectomy remained in our hands, and their principal antileukaemic treatment was busulphan in conventional dosage ( 
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It may be surprising that while in five of our patients the disease underwent metamorphosis no patient developed myelofibrosis. Only further follow-up of these and other cases can tell whether or not early splenectomy may favourably influence C.G.L., not only as regards the occurrence of metamorphosis but as regards the complicating feature of myelofibrosis.
The most probable explanation of our results is that splenectomy postponed the metamorphosis of C.G.L. from a chronic to an acute phase. The results do not prove this hypothesis beyond reasonable doubt but they do show that splenectomy in C.G.L. is reasonably safe and without obvious adverse effects on prognosis, and they support the need for the controlled clinical trial of splenectomy 'in C.G.L. which the Medical Research Council has inaugurated. We cannot agree with the recommendation (Schwarzenberg et al., 1973) Significance level by 1-tailed normal approximation P < 0.05
In selecting control patients from the M.R.C. series a four-month correction factor was introduced to compensate for possible selection of patients in the splenectomy series, in that the appearance of unexplained symptoms or of anaemia might have prevented splenectomy in a patient under our care. Such symptoms can occur up to three or four months before metamorphosis of C.G.L. is haematologically apparent and could have prevented a patient whose C.G.L. was destined to undergo metamorphosis in the near future from being entered into our series. In fact, no patients were actually excluded on the basis. If the correction factor of four months is omitted the results then develop a higher level of significance (P < 0 02), since about 12 cases of metamorphosis of C.G.L. would then have been expected in the splenectomized patients. The time when splenectomy was undertaken depended upon the time taken by each of our patients to achieve clinical remission of his C.G.L., but this is unlikely to have introduced a bias since in the M.R.C. series no correlation existed between the time taken to achieve remission and ultimate prognosis. girls and is characterized by loss of weight and secondary amenorrhoea. It is generally considered that the disorder is psychologically precipitated and involves mechanisms concerned with the ouput of gonadotrophins (Crisp, 1967; Russell, 1970) . When much weight is lost gonadotrophin and gonadal steroid levels are low but recover as weight is restored (Marshall and Russell Fraser, 1971; Beumont et al., 1973; Crisp et al., 1973) though cyclical bleeding in women rarely resumes until normal weight is regained and may even then be delayed (Kay and Leigh, 1954; Crisp and Stonehill, 1971 ).
The present investigation was undertaken to assess the sensitivity of the anterior pituitary to gonadotrophin-releasing hormone (luteinizing hormone/follicle-stimulating hormonereleasing hormone (LH/FSH-RH)) in patients with anorexia nervosa at different stages of treatment.
Twelve women and two men with primary anorexia nervosa of at least six months duration and of the "abstaining" kind (Crisp, 1967) were studied at various stages of their treatment at St. George's Hospital, London. Four of the women and one man were tested on two or more occasions, once at a low weight and again when normal weight had been regained. The treatment regimen for these patients aimed at restoring their weight to the population mean norm (Kemsley, 1952) for their sex, height, and age at onset of the illness ("target weight"). Relevant 
